These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. Ushijima T; Yoshino T Cancer Res; 2016 Nov; 76(22):6443-6444. PubMed ID: 28148677 [No Abstract] [Full Text] [Related]
5. Personalized treatment for patients with colorectal cancer: role of biomarkers. Duffy MJ Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438 [TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. De Mattia E; Cecchin E; Toffoli G Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741 [TBL] [Abstract][Full Text] [Related]
7. Precision cancer medicine: where to target? Yu Q; Ding J Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154 [No Abstract] [Full Text] [Related]
8. Drug development: Mix and match. Scudellari M Nature; 2015 May; 521(7551):S12-4. PubMed ID: 25970452 [No Abstract] [Full Text] [Related]
10. Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Patil H; Saxena SG; Barrow CJ; Kanwar JR; Kapat A; Kanwar RK Drug Discov Today; 2017 Jan; 22(1):111-119. PubMed ID: 27693431 [TBL] [Abstract][Full Text] [Related]
11. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689 [TBL] [Abstract][Full Text] [Related]
12. Delivering on the promise of precision cancer medicine. Berger MF; Van Allen EM Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852 [No Abstract] [Full Text] [Related]
13. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Chen G; Yang Z; Eshleman JR; Netto GJ; Lin MT Biomed Res Int; 2016; 2016():9850690. PubMed ID: 27699178 [TBL] [Abstract][Full Text] [Related]
14. Transcriptome modeling and phenotypic assays for cancer precision medicine. Jeong E; Moon SU; Song M; Yoon S Arch Pharm Res; 2017 Aug; 40(8):906-914. PubMed ID: 28766239 [TBL] [Abstract][Full Text] [Related]
15. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy]. Lai M Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564 [No Abstract] [Full Text] [Related]
16. Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer. Lieberman R Am J Ther; 2009; 16(6):477-9. PubMed ID: 19829092 [No Abstract] [Full Text] [Related]
17. Pairing Cancer Biomarkers to Biomedicine. Shin SH; Dong Z EBioMedicine; 2017 Nov; 25():1-2. PubMed ID: 29113773 [No Abstract] [Full Text] [Related]
18. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E Drug Resist Updat; 2011 Dec; 14(6):280-96. PubMed ID: 21955833 [TBL] [Abstract][Full Text] [Related]
19. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer? Hawkes E; Cunningham D Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017 [No Abstract] [Full Text] [Related]
20. Editorial. Approaches to personalized medicine in oncology--the 9th Annual Meeting of CESAR in Greifswald. Ritter C; Sehrt D; Jaehde U Int J Clin Pharmacol Ther; 2012 Jan; 50(1):53-4. PubMed ID: 22192647 [No Abstract] [Full Text] [Related] [Next] [New Search]